- Home
- MDB vs GMAB Comparison
MDB vs GMAB Comparison
Compare MDB & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDB
- GMAB
- Stock Information
- Founded
- MDB 2007
- GMAB 1999
- Country
- MDB United States
- GMAB Denmark
- Employees
- MDB N/A
- GMAB N/A
- Industry
- MDB Computer Software: Prepackaged Software
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MDB Technology
- GMAB Health Care
- Exchange
- MDB Nasdaq
- GMAB Nasdaq
- Market Cap
- MDB 15.8B
- GMAB 13.7B
- IPO Year
- MDB 2017
- GMAB N/A
- Fundamental
- Price
- MDB $201.50
- GMAB $21.16
- Analyst Decision
- MDB Strong Buy
- GMAB Buy
- Analyst Count
- MDB 30
- GMAB 9
- Target Price
- MDB $289.57
- GMAB $39.17
- AVG Volume (30 Days)
- MDB 2.9M
- GMAB 1.2M
- Earning Date
- MDB 06-04-2025
- GMAB 08-07-2025
- Dividend Yield
- MDB N/A
- GMAB N/A
- EPS Growth
- MDB N/A
- GMAB 276.80
- EPS
- MDB N/A
- GMAB 18.36
- Revenue
- MDB $2,104,896,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- MDB $15.18
- GMAB $747.74
- Revenue Next Year
- MDB $15.92
- GMAB $14.81
- P/E Ratio
- MDB N/A
- GMAB $1.15
- Revenue Growth
- MDB 19.24
- GMAB 25.43
- 52 Week Low
- MDB $140.78
- GMAB $17.24
- 52 Week High
- MDB $370.00
- GMAB $28.56
- Technical
- Relative Strength Index (RSI)
- MDB 52.59
- GMAB 45.96
- Support Level
- MDB $200.35
- GMAB $22.70
- Resistance Level
- MDB $218.12
- GMAB $23.13
- Average True Range (ATR)
- MDB 8.19
- GMAB 0.39
- MACD
- MDB -1.33
- GMAB -0.13
- Stochastic Oscillator
- MDB 33.35
- GMAB 12.44
About MDB MongoDB Inc.
Founded in 2007, MongoDB is a vendor of a document-oriented database that accelerates development processes of new applications. Enterprise customers can choose between the fully managed offering, MongoDB Atlas, or the self-managed version, MongoDB Enterprise Advanced. MongoDB is a popular tool among developers, and its free Community Server has recorded over 500 million downloads since 2009.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.